Abstract 1939P
Background
Cancer-associated inflammation is an established cofactor of tumor development and progression. In thyroid carcinoma (TC) immunotherapy is gaining ground, with tumors displaying a diverse inflammatory cell infiltrate and expression of cytokines. Although an association between inflammation and TC is recognized, a cause-effect relationship at the molecular level is not understood. In mice, inducible targeting of BRAFV600E to thyroid follicular cells by Cre recombinase linked to thyroglobulin promotor (TgCreER T2 ) give rise to papillary TC. However, synchronous expression of Braf in most thyroid cells causes grave reduction in tumor surrounding tissue, obstructing microenvironment studies and obscures early changes. Omitting induction in TgCreER T2 ;Braf CA/+ mice, utilizing “Cre leakiness”, TC is developed spontaneously in a preserved microenvironment. Here, we explored inflammatory contribution to carcinogenesis in TgCreER T2 ;Braf CA/+ mice by characterizing major pro-inflammatory cytokines encompassing early and later tumor stages and the effect of Braf kinase inhibition.
Methods
Thyroids of TgCreER T2 ;Braf CA/+ mice were analyzed by qPCR and western blot protein expression profiling of cytokines Tnf-a, IL1b and IL6 at 1, 3, 6 and 12 months of age. To investigate reversibility of the inflammatory response to BrafCA/+ activation, mutant mice aged 6 months were fed with Braf kinase inhibitor Vemurafenib (PLX4720) or control dietary pellets for 4 weeks.
Results
All cytokines showed a gradual increase of gene expression between age 1 to 6 months in non-induced mutant mice, and a subsequent decrease at 12 months. Western blot confirmed upregulation of protein expression at age 1 to 6 months, and a further increase at 12 months. Interindividual variation of expression was high at all ages. The PLX4720-treated cohort had significant reduction of cytokine and protein expression compared to the untreated.
Conclusions
Inflammatory response due to Braf activation is an early event in thyroid carcinoma development, with a time-course dependent expression pattern. Targeted Braf inhibition significantly down-regulates cytokine expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mikael Nilsson Sahlgrenska Centre for Cancer Research, Institute of Biomedicine, Gothenburg university Gothenburg, Sweden.
Funding
Cancerfonden (Swedish Cancer Society).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18
1929P - Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Presenter: Laura Locati
Session: Poster session 18
1930P - Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Presenter: Jiaxin Niu
Session: Poster session 18
1931P - Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Presenter: Winston Wong
Session: Poster session 18
1932P - Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Presenter: Silvia Marchesi
Session: Poster session 18
1933P - Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Presenter: Raffaele Ciampi
Session: Poster session 18
1934P - Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study
Presenter: Yan Hu
Session: Poster session 18
1935P - Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Presenter: Sergio Pérez Fernandez
Session: Poster session 18